Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.33-
QQQ
716.250.03%
BTC/USD
77500.800.4345%
DIA
535.550.09%
GLD
409.230.08%
TLT
82.940.07%

Acumen Pharmaceuticals Inc

ABOSNASDAQ
Trade with Public
Trade with Public
$2.92
-0.11-3.63%
At close: Aug 28, 5:00 PM EST
$3.10
0.186.16%
After Hours: 9:19 AM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Acumen Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Acumen Pharmaceuticals (ABOS).

Price Target Range — 10 Quarters

Analyst Consensus — 6 Analysts

6Buy
Consensus RatingBuy# Analysts6Avg. Consensus PT$7Upside to Avg. PT+130.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Mar 26, 2026BTIGThomas ShraderMaintainedBuy$8
Mar 16, 2026BTIGThomas ShraderPT RaiseBuy$7→$8
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
BTIG Reiterates Buy on Acumen Pharmaceuticals, Maintains $8 Price Target

BTIG analyst Thomas Shrader reiterates Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and maintains $8 price target.
Benzinga Newsdesk

Baker Hughes To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Tuesday

Avi Kapoor

PRO
BTIG Maintains Buy on Acumen Pharmaceuticals, Raises Price Target to $7

BTIG analyst Thomas Shrader maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and raises the price target from $4 to $7.
Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on Acumen Pharmaceuticals, Lowers Price Target to $8

B of A Securities analyst Geoff Meacham maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and lowers the price target from $9 to $8.
Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on Acumen Pharmaceuticals, Lowers Price Target to $9

B of A Securities analyst Geoff Meacham maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and lowers the price target from $10 to $9.
Benzinga Newsdesk

PRO
Citigroup Initiates Coverage On Acumen Pharmaceuticals with Buy Rating, Announces Price Target of $4

Citigroup analyst Geoff Meacham initiates coverage on Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy rating and announces Price Target of $4.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved